Innovus Pharmaceuticals, Inc. announced that it has entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals Corporation. The Agreement with Acerus represents one of the first international license and distribution agreements for Innovus Pharma for one of its core multi-million dollar U.S. products. Under the agreement, Innovus Pharma will receive an up-front license payment and is eligible to receive up to CAD 1.65 million dollars in sales milestone payments plus minimum order quantities at an agreed-upon transfer price. UriVarx® is a Natural Health Product (NHP) approved by Health Canada that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. The product will be offered by Acerus over-the-counter to Canadians dealing with such symptoms. Nearly 1 in 5 Canadians over the age of 35 experience overactive bladder symptoms1. Men and women’s lives are directly impacted by an overactive bladder, and the current treatment options may come with systemic side effects.